Lonza to manufacture GSK’s Arzerra

Related tags Pharmacology Food and drug administration Pharmaceutical drug

Lonza is manufacturing GlaxoSmithKline’s (GSK) and Genmab’s antibody Arzerra (ofatumumab), which was recently approved by the FDA, under a long-term supply deal.

The contract manufacturing organisation (CMO) performed process development and current good manufacturing practice (cGMP) compliant production to support the licensure and has now expanded on this arrangement.

Stephan Kutzer, chief operating officer at Lonza Custom Manufacturing APIs (active pharmaceutical ingredients), said he expects Arzerra to “be a key biopharmaceutical for both companies​”.

He added that Lonza has drawn on “the expertise of both companies to develop a state-of-the-art manufacturing process​”. Arzerra is a treatment for chronic lymphocytic leukemia (CLL) that recently gained approval from the US Food and Drug Administration (FDA).

Related topics Contract Manufacturing & Logistics

Related news

Show more

Follow us


View more